Anti-Viral Drugs Market Research Report By Drug Type (Nucleotide Analogues, Protease Inhibitors, Reverse Transcriptase Inhibitors, Entry Inhibitors), By Therapeutic Area (HIV, Hepatitis, Influenza, COVID-19), By Route of Administration (Oral, Intravenous, Topical), By End User (Hospitals, Clinics, Home Care) and By Regional (North America, Europe, South America, Asia-Pacific, Middle East and Africa)- Forecast to 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

1.1. Market Overview

1.2. Key Findings

1.3. Market Segmentation

1.4. Competitive Landscape

1.5. Challenges and Opportunities

1.6. Future Outlook

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the study

2.2.1. Research Objective

2.2.2. Assumption

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value chain Analysis

5.2. Porter's Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. ANTI-VIRAL DRUGS MARKET, BY DRUG TYPE (USD BILLION)

6.1. Nucleotide Analogues

6.2. Protease Inhibitors

6.3. Reverse Transcriptase Inhibitors

6.4. Entry Inhibitors

7. ANTI-VIRAL DRUGS MARKET, BY THERAPEUTIC AREA (USD BILLION)

7.1. HIV

7.2. Hepatitis

7.3. Influenza

7.4. COVID-19

8. ANTI-VIRAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION (USD BILLION)

8.1. Oral

8.2. Intravenous

8.3. Topical

9. ANTI-VIRAL DRUGS MARKET, BY END USER (USD BILLION)

9.1. Hospitals

9.2. Clinics

9.3. Home Care

10. ANTI-VIRAL DRUGS MARKET, BY REGIONAL (USD BILLION)

10.1. North America

10.1.1. US

10.1.2. Canada

10.2. Europe

10.2.1. Germany

10.2.2. UK

10.2.3. France

10.2.4. Russia

10.2.5. Italy

10.2.6. Spain

10.2.7. Rest of Europe

10.3. APAC

10.3.1. China

10.3.2. India

10.3.3. Japan

10.3.4. South Korea

10.3.5. Malaysia

10.3.6. Thailand

10.3.7. Indonesia

10.3.8. Rest of APAC

10.4. South America

10.4.1. Brazil

10.4.2. Mexico

10.4.3. Argentina

10.4.4. Rest of South America

10.5. MEA

10.5.1. GCC Countries

10.5.2. South Africa

10.5.3. Rest of MEA

11. COMPETITIVE LANDSCAPE

11.1. Overview

11.2. Competitive Analysis

11.3. Market share Analysis

11.4. Major Growth Strategy in the Anti-Viral Drugs Market

11.5. Competitive Benchmarking

11.6. Leading Players in Terms of Number of Developments in the Anti-Viral Drugs Market

11.7. Key developments and growth strategies

11.7.1. New Product Launch/Service Deployment

11.7.2. Merger & Acquisitions

11.7.3. Joint Ventures

11.8. Major Players Financial Matrix

11.8.1. Sales and Operating Income

11.8.2. Major Players R&D Expenditure. 2023

12. COMPANY PROFILES

12.1. BristolMyers Squibb

12.1.1. Financial Overview

12.1.2. Products Offered

12.1.3. Key Developments

12.1.4. SWOT Analysis

12.1.5. Key Strategies

12.2. Sanofi

12.2.1. Financial Overview

12.2.2. Products Offered

12.2.3. Key Developments

12.2.4. SWOT Analysis

12.2.5. Key Strategies

12.3. HoffmannLa Roche

12.3.1. Financial Overview

12.3.2. Products Offered

12.3.3. Key Developments

12.3.4. SWOT Analysis

12.3.5. Key Strategies

12.4. AbbVie

12.4.1. Financial Overview

12.4.2. Products Offered

12.4.3. Key Developments

12.4.4. SWOT Analysis

12.4.5. Key Strategies

12.5. Teva Pharmaceutical Industries

12.5.1. Financial Overview

12.5.2. Products Offered

12.5.3. Key Developments

12.5.4. SWOT Analysis

12.5.5. Key Strategies

12.6. Gilead Sciences

12.6.1. Financial Overview

12.6.2. Products Offered

12.6.3. Key Developments

12.6.4. SWOT Analysis

12.6.5. Key Strategies

12.7. Bayer

12.7.1. Financial Overview

12.7.2. Products Offered

12.7.3. Key Developments

12.7.4. SWOT Analysis

12.7.5. Key Strategies

12.8. Amgen

12.8.1. Financial Overview

12.8.2. Products Offered

12.8.3. Key Developments

12.8.4. SWOT Analysis

12.8.5. Key Strategies

12.9. GlaxoSmithKline

12.9.1. Financial Overview

12.9.2. Products Offered

12.9.3. Key Developments

12.9.4. SWOT Analysis

12.9.5. Key Strategies

12.10. Johnson and Johnson

12.10.1. Financial Overview

12.10.2. Products Offered

12.10.3. Key Developments

12.10.4. SWOT Analysis

12.10.5. Key Strategies

12.11. Pfizer

12.11.1. Financial Overview

12.11.2. Products Offered

12.11.3. Key Developments

12.11.4. SWOT Analysis

12.11.5. Key Strategies

12.12. Roche

12.12.1. Financial Overview

12.12.2. Products Offered

12.12.3. Key Developments

12.12.4. SWOT Analysis

12.12.5. Key Strategies

12.13. Merck and Co

12.13.1. Financial Overview

12.13.2. Products Offered

12.13.3. Key Developments

12.13.4. SWOT Analysis

12.13.5. Key Strategies

12.14. AstraZeneca

12.14.1. Financial Overview

12.14.2. Products Offered

12.14.3. Key Developments

12.14.4. SWOT Analysis

12.14.5. Key Strategies

12.15. Novartis

12.15.1. Financial Overview

12.15.2. Products Offered

12.15.3. Key Developments

12.15.4. SWOT Analysis

12.15.5. Key Strategies

13. APPENDIX

13.1. References

13.2. Related Reports

LIST OF TABLES

TABLE 1. LIST OF ASSUMPTIONS

TABLE 2. NORTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 3. NORTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 4. NORTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 5. NORTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 6. NORTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 7. US ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 8. US ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 9. US ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 10. US ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 11. US ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 12. CANADA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 13. CANADA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 14. CANADA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 15. CANADA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 16. CANADA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 17. EUROPE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 18. EUROPE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 19. EUROPE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 20. EUROPE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 21. EUROPE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 22. GERMANY ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 23. GERMANY ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 24. GERMANY ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 25. GERMANY ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 26. GERMANY ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 27. UK ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 28. UK ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 29. UK ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 30. UK ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 31. UK ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 32. FRANCE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 33. FRANCE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 34. FRANCE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 35. FRANCE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 36. FRANCE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 37. RUSSIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 38. RUSSIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 39. RUSSIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 40. RUSSIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 41. RUSSIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 42. ITALY ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 43. ITALY ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 44. ITALY ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 45. ITALY ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 46. ITALY ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 47. SPAIN ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 48. SPAIN ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 49. SPAIN ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 50. SPAIN ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 51. SPAIN ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 52. REST OF EUROPE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 53. REST OF EUROPE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 54. REST OF EUROPE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 55. REST OF EUROPE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 56. REST OF EUROPE ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 57. APAC ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 58. APAC ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 59. APAC ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 60. APAC ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 61. APAC ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 62. CHINA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 63. CHINA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 64. CHINA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 65. CHINA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 66. CHINA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 67. INDIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 68. INDIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 69. INDIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 70. INDIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 71. INDIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 72. JAPAN ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 73. JAPAN ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 74. JAPAN ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 75. JAPAN ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 76. JAPAN ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 77. SOUTH KOREA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 78. SOUTH KOREA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 79. SOUTH KOREA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 80. SOUTH KOREA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 81. SOUTH KOREA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 82. MALAYSIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 83. MALAYSIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 84. MALAYSIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 85. MALAYSIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 86. MALAYSIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 87. THAILAND ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 88. THAILAND ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 89. THAILAND ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 90. THAILAND ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 91. THAILAND ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 92. INDONESIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 93. INDONESIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 94. INDONESIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 95. INDONESIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 96. INDONESIA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 97. REST OF APAC ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 98. REST OF APAC ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 99. REST OF APAC ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 100. REST OF APAC ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 101. REST OF APAC ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 102. SOUTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 103. SOUTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 104. SOUTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 105. SOUTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 106. SOUTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 107. BRAZIL ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 108. BRAZIL ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 109. BRAZIL ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 110. BRAZIL ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 111. BRAZIL ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 112. MEXICO ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 113. MEXICO ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 114. MEXICO ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 115. MEXICO ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 116. MEXICO ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 117. ARGENTINA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 118. ARGENTINA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 119. ARGENTINA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 120. ARGENTINA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 121. ARGENTINA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 122. REST OF SOUTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 123. REST OF SOUTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 124. REST OF SOUTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 125. REST OF SOUTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 126. REST OF SOUTH AMERICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 127. MEA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 128. MEA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 129. MEA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 130. MEA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 131. MEA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 132. GCC COUNTRIES ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 133. GCC COUNTRIES ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 134. GCC COUNTRIES ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 135. GCC COUNTRIES ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 136. GCC COUNTRIES ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 137. SOUTH AFRICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 138. SOUTH AFRICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 139. SOUTH AFRICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 140. SOUTH AFRICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 141. SOUTH AFRICA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 142. REST OF MEA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY DRUG TYPE, 2019-2032 (USD BILLIONS)

TABLE 143. REST OF MEA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY THERAPEUTIC AREA, 2019-2032 (USD BILLIONS)

TABLE 144. REST OF MEA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY ROUTE OF ADMINISTRATION, 2019-2032 (USD BILLIONS)

TABLE 145. REST OF MEA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)

TABLE 146. REST OF MEA ANTI-VIRAL DRUGS MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)

TABLE 147. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL

TABLE 148. ACQUISITION/PARTNERSHIP

LIST OF FIGURES

FIGURE 1. MARKET SYNOPSIS

FIGURE 2. NORTH AMERICA ANTI-VIRAL DRUGS MARKET ANALYSIS

FIGURE 3. US ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 4. US ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 5. US ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 6. US ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 7. US ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 8. CANADA ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 9. CANADA ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 10. CANADA ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 11. CANADA ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 12. CANADA ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 13. EUROPE ANTI-VIRAL DRUGS MARKET ANALYSIS

FIGURE 14. GERMANY ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 15. GERMANY ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 16. GERMANY ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 17. GERMANY ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 18. GERMANY ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 19. UK ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 20. UK ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 21. UK ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 22. UK ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 23. UK ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 24. FRANCE ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 25. FRANCE ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 26. FRANCE ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 27. FRANCE ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 28. FRANCE ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 29. RUSSIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 30. RUSSIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 31. RUSSIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 32. RUSSIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 33. RUSSIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 34. ITALY ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 35. ITALY ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 36. ITALY ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 37. ITALY ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 38. ITALY ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 39. SPAIN ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 40. SPAIN ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 41. SPAIN ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 42. SPAIN ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 43. SPAIN ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 44. REST OF EUROPE ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 45. REST OF EUROPE ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 46. REST OF EUROPE ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 47. REST OF EUROPE ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 48. REST OF EUROPE ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 49. APAC ANTI-VIRAL DRUGS MARKET ANALYSIS

FIGURE 50. CHINA ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 51. CHINA ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 52. CHINA ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 53. CHINA ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 54. CHINA ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 55. INDIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 56. INDIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 57. INDIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 58. INDIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 59. INDIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 60. JAPAN ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 61. JAPAN ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 62. JAPAN ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 63. JAPAN ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 64. JAPAN ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 65. SOUTH KOREA ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 66. SOUTH KOREA ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 67. SOUTH KOREA ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 68. SOUTH KOREA ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 69. SOUTH KOREA ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 70. MALAYSIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 71. MALAYSIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 72. MALAYSIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 73. MALAYSIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 74. MALAYSIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 75. THAILAND ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 76. THAILAND ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 77. THAILAND ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 78. THAILAND ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 79. THAILAND ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 80. INDONESIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 81. INDONESIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 82. INDONESIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 83. INDONESIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 84. INDONESIA ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 85. REST OF APAC ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 86. REST OF APAC ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 87. REST OF APAC ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 88. REST OF APAC ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 89. REST OF APAC ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 90. SOUTH AMERICA ANTI-VIRAL DRUGS MARKET ANALYSIS

FIGURE 91. BRAZIL ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 92. BRAZIL ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 93. BRAZIL ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 94. BRAZIL ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 95. BRAZIL ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 96. MEXICO ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 97. MEXICO ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 98. MEXICO ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 99. MEXICO ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 100. MEXICO ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 101. ARGENTINA ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 102. ARGENTINA ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 103. ARGENTINA ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 104. ARGENTINA ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 105. ARGENTINA ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 106. REST OF SOUTH AMERICA ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 107. REST OF SOUTH AMERICA ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 108. REST OF SOUTH AMERICA ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 109. REST OF SOUTH AMERICA ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 110. REST OF SOUTH AMERICA ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 111. MEA ANTI-VIRAL DRUGS MARKET ANALYSIS

FIGURE 112. GCC COUNTRIES ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 113. GCC COUNTRIES ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 114. GCC COUNTRIES ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 115. GCC COUNTRIES ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 116. GCC COUNTRIES ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 117. SOUTH AFRICA ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 118. SOUTH AFRICA ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 119. SOUTH AFRICA ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 120. SOUTH AFRICA ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 121. SOUTH AFRICA ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 122. REST OF MEA ANTI-VIRAL DRUGS MARKET ANALYSIS BY DRUG TYPE

FIGURE 123. REST OF MEA ANTI-VIRAL DRUGS MARKET ANALYSIS BY THERAPEUTIC AREA

FIGURE 124. REST OF MEA ANTI-VIRAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

FIGURE 125. REST OF MEA ANTI-VIRAL DRUGS MARKET ANALYSIS BY END USER

FIGURE 126. REST OF MEA ANTI-VIRAL DRUGS MARKET ANALYSIS BY REGIONAL

FIGURE 127. KEY BUYING CRITERIA OF ANTI-VIRAL DRUGS MARKET

FIGURE 128. RESEARCH PROCESS OF MRFR

FIGURE 129. DRO ANALYSIS OF ANTI-VIRAL DRUGS MARKET

FIGURE 130. DRIVERS IMPACT ANALYSIS: ANTI-VIRAL DRUGS MARKET

FIGURE 131. RESTRAINTS IMPACT ANALYSIS: ANTI-VIRAL DRUGS MARKET

FIGURE 132. SUPPLY / VALUE CHAIN: ANTI-VIRAL DRUGS MARKET

FIGURE 133. ANTI-VIRAL DRUGS MARKET, BY DRUG TYPE, 2024 (% SHARE)

FIGURE 134. ANTI-VIRAL DRUGS MARKET, BY DRUG TYPE, 2019 TO 2032 (USD Billions)

FIGURE 135. ANTI-VIRAL DRUGS MARKET, BY THERAPEUTIC AREA, 2024 (% SHARE)

FIGURE 136. ANTI-VIRAL DRUGS MARKET, BY THERAPEUTIC AREA, 2019 TO 2032 (USD Billions)

FIGURE 137. ANTI-VIRAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)

FIGURE 138. ANTI-VIRAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019 TO 2032 (USD Billions)

FIGURE 139. ANTI-VIRAL DRUGS MARKET, BY END USER, 2024 (% SHARE)

FIGURE 140. ANTI-VIRAL DRUGS MARKET, BY END USER, 2019 TO 2032 (USD Billions)

FIGURE 141. ANTI-VIRAL DRUGS MARKET, BY REGIONAL, 2024 (% SHARE)

FIGURE 142. ANTI-VIRAL DRUGS MARKET, BY REGIONAL, 2019 TO 2032 (USD Billions)

FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS